Clinical Trial Update: Apatinib, Irinotecan and S-1 (ApaIRIS) in Treating Patients With Metastatic Pancreatic Cancer After AG Regimen [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating ApaIRIS (Apatinib, Irinotecan, and S-1) for metastatic pancreatic cancer after AG regimen.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• ApaIRIS (Apatinib, Irinotecan, and S-1)

Snippet

Sponsor: Fudan University | Conditions: Metastatic Pancreatic Cancer | Phase 2 | Status: UNKNOWN